PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 17 | 1 | 42–48
Article title

Liponerv – nowe możliwości pomocy chorym z łagodnymi zaburzeniami poznawczymi

Content
Title variants
EN
Liponerv – new possibilities for helping patients with mild cognitive impairment
Languages of publication
PL
Abstracts
EN
Mild cognitive impairment is a clinical state that is defined as intermediate between normal functioning and the first stage of dementia. It involves the deterioration of memory and other cognitive areas. With time some patients develop Alzheimer’s disease-related dementia. As societies age, the prevalence of such symptoms is likely to increase dramatically. Multiple observations indicate an important role of polyunsaturated omega-3 fatty acids in limiting the progression of brain lesions. This is due to the fact that these acids influence pathological processes associated with neurodegeneration such as beta-amyloid accumulation, chronic inflammation, oxidative stress and accelerated apoptosis. In recent years many protective mechanisms of action of fatty acids have been described, including multidirectional inhibition of beta-amyloid toxicity, anti-inflammatory and neuroprotective action of their metabolites, reduction of cellular damage in response to oxidative stress and stimulation of neural cell growth and differentiation. Alpha-lipoic acid is a strong antioxidant which may help to protect polyunsaturated fatty acids and additionally inhibit neuronal damage. Liponerv is a new formulation which contains both acids: DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), and alpha-lipoic acid. The combination of these two ingredients was evaluated in a pilot clinical study which demonstrated an improvement in everyday cognitive and instrumental abilities of patients with diagnosed Alzheimer’s disease. A number of studies indicate that long-term administration of such a combination may have a positive impact on the condition of brain tissue in individuals without dementia who experience deterioration in their cognitive abilities. Liponerv may be an interesting supplementary therapeutic option in the overall management of these patients. It should undoubtedly be characterised by safety of use and good tolerability, which is indicated by clinical experience with similar products.
PL
Łagodne zaburzenia poznawcze to stan kliniczny określany jako pośredni między normalnym funkcjonowaniem a pierwszym etapem otępienia. Dochodzi w nim do osłabienia pamięci lub innych obszarów kognitywnych. U części pacjentów z czasem rozwija się otępienie o typie choroby Alzheimera. Wraz ze starzeniem się społeczeństw częstość występowania takich objawów prawdopodobnie będzie dynamicznie wzrastać. Wiele obserwacji wskazuje na istotną rolę wielonienasyconych kwasów tłuszczowych w ograniczaniu postępu zmian mózgowych – kwasy te wywierają bowiem wpływ na procesy patologiczne w przebiegu neurodegeneracji, takie jak odkładanie beta-amyloidu, przewlekły stan zapalny, stres oksydacyjny i przyspieszona apoptoza. W ostatnich latach opisano wiele mechanizmów ochronnego działania kwasów tłuszczowych, w tym wielokierunkowe hamowanie toksyczności beta-amyloidu, działanie przeciwzapalne i neuroprotekcyjne ich metabolitów, zmniejszenie uszkodzenia komórkowego w odpowiedzi na stres oksydacyjny, pobudzanie wzrostu i różnicowania komórek nerwowych. Kwas alfa-liponowy jest silnym przeciwutleniaczem, który może pomagać w protekcji wielonienasyconych kwasów tłuszczowych i dodatkowo hamować uszkodzenie neuronalne. Liponerv to nowy preparat, zawierający zarówno kwasy tłuszczowe DHA (kwas dokozaheksaenowy), EPA (kwas eikozapentaenowy), jak i kwas alfa-liponowy. Kombinacja tych składników była przedmiotem oceny w pilotowym badaniu klinicznym, w którym wykazano poprawę funkcji poznawczych i instrumentalnych aktywności życia codziennego u chorych z rozpoznaną chorobą Alzheimera. Wyniki szeregu badań wskazują, że długotrwałe podawanie takiej kombinacji może mieć korzystny wpływ na kondycję tkanki mózgowej u osób bez otępienia, które odczuwają pogorszenie zdolności poznawczych. Liponerv może być interesującą opcją terapeutyczną jako uzupełniający element w całościowym postępowaniu u tych chorych. Niewątpliwą jego zaletą powinno być bezpieczeństwo stosowania i dobra tolerancja, na co wskazują doświadczenia kliniczne z podobnymi produktami.
Discipline
Publisher

Year
Volume
17
Issue
1
Pages
42–48
Physical description
Contributors
  • Qpharma Sp. z o.o., Warszawa, Polska
References
  • Akbar M, Calderon F, Wen Z et al.: Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A 2005; 102: 10858–10863.
  • Barberger-Gateau P, Letenneur L, Deschamps V et al.: Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325: 932–933.
  • Barberger-Gateau P, Raffaitin C, Letenneur L et al.: Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007; 69: 1921–1930.
  • Belayev L, Khoutorova L, Atkins KD et al.: Docosahexaenoic acid therapy of experimental ischemic stroke. Transl Stroke Res 2011; 2: 33–41.
  • Boston PF, Bennett A, Horrobin DF et al.: Ethyl-EPA in Alzheimer’s disease – a pilot study. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 341–346.
  • Calderon F, Kim HY: Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 2004; 90: 979–988.
  • Cao D, Kevala K, Kim J et al.: Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 2009; 111: 510–521.
  • Chiu CC, Su KP, Cheng TC et al.: The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1538–1544.
  • Cole GM, Frautschy SA: DHA may prevent age-related dementia. J Nutr 2010; 140: 869–874.
  • Cole GM, Ma QL, Frautschy SA: Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 213–221.
  • DeCarli C: Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15–21.
  • Farooqui AA, Horrocks LA, Farooqui T: Modulation of inflammation in brain: a matter of fat. J Neurochem 2007; 101: 577–599.
  • Fava A, Pirritano D, Plastino M et al.: The effect of lipoic acid therapy on cognitive functioning in patients with Alzheimer’s disease. J Neurodegener Dis 2013; 2013: 454253.
  • Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al.: ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402–1408.
  • Gamoh S, Hashimoto M, Hossain S et al.: Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 2001; 28: 266–270.
  • Gamoh S, Hashimoto M, Sugioka K et al.: Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 1999; 93: 237–241.
  • van Gelder BM, Tijhuis M, Kalmijn S et al.: Fish consumption, n–3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85: 1142–1147.
  • Hager K, Kenklies M, McAfoose J et al.: Alpha-lipoic acid as a new treatment option for Alzheimer’s disease – a 48 months follow-up analysis. J Neural Transm Suppl 2007; (72): 189–193.
  • Hjorth E, Zhu M, Toro VC et al.: Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 2013; 35: 697–713.
  • Holmquist L, Stuchbury G, Berbaum K et al.: Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol Ther 2007; 113: 154–164.
  • Hooijmans CR, Pasker-de Jong PC, de Vries RB et al.: The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer’s pathology in animal models of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2012; 28: 191–209.
  • Kawakita E, Hashimoto M, Shido O: Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006; 139: 991–997.
  • Kotani S, Sakaguchi E, Warashina S et al.: Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56: 159–164.
  • Lee LK, Shahar S, Chin AV et al.: Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013; 225: 605–612.
  • Lukiw WJ, Cui JG, Marcheselli VL et al.: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774–2783.
  • Maczurek A, Hager K, Kenklies M et al.: Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev 2008; 60: 1463–1470.
  • Marcheselli VL, Hong S, Lukiw WJ et al.: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807–43817.
  • Mazereeuw G, Lanctôt KL, Chau SA et al.: Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging 2012; 33: 1482.e17–1482.e29.
  • Morris MC, Evans DA, Tangney CC et al.: Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62: 1849–1853.
  • Mukherjee PK, Marcheselli VL, Serhan CN et al.: Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 2004; 101: 8491–8496.
  • Nowak JZ: Przeciwzapalne „prowygaszeniowe” pochodne wielonienasyconych kwasów tłuszczowych omega 3 i omega 6. Postępy Hig Med Dośw (online) 2010; 64: 115–132.
  • Okhravi HR, Palmer RM: Mild cognitive impairment: challenges in research and in practice. Cleve Clin J Med 2012; 79: 853–854.
  • Petersen RC, Smith GE, Waring SC et al.: Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997; 9 Suppl 1: 65–69.
  • Puskás LG1, Kitajka K, Nyakas C et al.: Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci U S A 2003; 100: 1580–1585.
  • Quinn JF, Raman R, Thomas RG et al.: Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304: 1903–1911.
  • Rao JS, Ertley RN, Lee HJ et al.: n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPKdependent mechanism. Mol Psychiatry 2007; 12: 36–46.
  • Reisberg B, Ferris SH, de Leon MJ et al.: Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res 1988; 15: 101–114.
  • Schaefer EJ, Bongard V, Beiser AS et al.: Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63: 1545–1550.
  • Serhan CN: Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010; 177: 1576–1591.
  • Shinto L, Quinn J, Montine T et al.: A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 2014; 38: 111–120.
  • Sinn N, Milte CM, Street SJ et al.: Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107: 1682–1693.
  • Tanaka K, Farooqui AA, Siddiqi NJ et al.: Effects of docosahexaenoic acid on neurotransmission. Biomol Ther (Seoul) 2012; 20: 152–157.
  • Unverzagt FW, Gao S, Baiyewu O et al.: Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology 2001; 57: 1655–1662.
  • Vakhapova V, Cohen T, Richter Y et al.: Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in nondemented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord 2010; 29: 467–474.
  • Yurko-Mauro K, McCarthy D, Rom D et al.: Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6: 456–464.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-68bc6d71-1cdb-43c3-afa3-f2484b57b044
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.